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Abstract: We review the epidemiology, pathophysiology, and etiology of cystoid macular edema 
(CME). Inﬂ  ammatory, diabetic, post-cataract, and macular edema due to age-related macular 
degeneration is described. The role of chronic inﬂ  ammation and hypoxia and direct macular traction 
is evaluated in each case according to different views from the literature. The different diagnostic 
methods for evaluating the edema are described. Special attention is given to ﬂ  uoroangiography 
and the most modern methods of macula examination, such as ocular coherence tomography and 
multifocal electroretinography. Finally, we discuss the treatment of cystoid macular edema in 
relation to its etiology. In this chapter we brieﬂ  y refer to the therapeutic value of laser treatment 
especially in diabetic maculopathy or vitrectomy in some selected cases. Our paper is focused 
mainly on recent therapeutic treatment with intravitreal injection of triamcinolone acetonide and 
anti-VEGF factors like bevacizumab (Avastin), ranibizumab (Lucentis), pegaptamid (Macugen), 
and others. The goal of this paper is to review the current status of this treatment for macular 
edema due to diabetic maculopathy, central retinal vein occlusion and post-cataract surgery. For 
this reason the results of recent multicenter clinical trials are quoted, as also our experience on the 
use of intravitreal injections of anti-VEGF factors and we discuss its value in clinical practice.
Keywords: cystoid macular edema, anti-VEGF, fluoroangiography, OCT, multifocal 
electroretinography
Introduction
Cystoid macular edema (CME) represents a common pathologic sequel of the retina 
and occurs in a variety of pathological conditions such as intraocular inﬂ  ammation, 
central or branch retinal vein occlusion, diabetic retinopathy and most commonly 
following cataract extraction. Histological studies show that radially orientated cystoid 
spaces consisting of ophthalmoscopically clear ﬂ  uid are often clinically detectable in 
the macula area. These cysts seem to be areas of retina in which the cells have been 
displaced. In this review a brief synopsis is done about the pathophysiology and etiology 
of CME, the different diagnostic methods for evaluating the CME are described and 
ﬁ  nally the therapeutic approaches of the disease are evaluated.
Etiology: Pathogenesis
Ocular inﬂ  ammatory diseases
CME in uveitis
The exact pathogenesis of CME remains uncertain. CME develops when excess ﬂ  uid 
accumulates within the macular retina. This is thought to occur following disruption 
of the blood–retinal barrier (BRB). Fluorescein angiography in the normal eye 
demonstrates the intact barrier well as the dye stays within blood vessels and does not 
leak into the retinal tissues. In particular, the avascular zone at the macula remains 
dark with no egress of dye. When the BRB is damaged, ﬂ  uid accumulates within the 
retina both intra- and extracellularly (Yanoff et al 1984).
Extracellular ﬂ  uid accumulation disturbs cell function and retinal architecture. 
Müller cells are thought to play an important role in acting as metabolic pumps which Clinical Ophthalmology 2008:2(4) 920
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keep the macula dehydrated. However, intracellular ﬂuid 
accumulation in the Müller cells may also occur in CME and 
further reduce macular retinal function. Vitreous traction may 
also play a part as demonstrated by the ﬁndings of Hirokawa 
and colleagues (1985) who showed that uveitic eyes with 
complete vitreous detachment tend to have fewer macular 
changes than those eyes without complete vitreous detachment. 
Hikichi and Trempe (1993) reported on 116 eyes with uveitis 
and demonstrated the importance of an attached vitreous: it 
was present in 78% of eyes with CME vs 22% of eyes without 
CME. In eyes with uveitis, damage to the integrity of the BRB 
results in leakage of dye during ﬂuorescein angiography which 
accumulates in the macular area, often with a characteristic 
petalloid appearance.
Numerous different T-cell cytokines have been detected in 
both the intraocular ﬂuids of inﬂamed eyes and the biopsies of 
involved ocular tissue and it is thought that cytokines such as 
interferon-γ, interleukin-2, interleukin-10, and tumor necrosis 
factor-α are key players in the generation of intraocular 
inﬂammation (Wakeﬁeld and Lloyd 1992). Other inﬂammatory 
mediators such as prostaglandins and chemokines are secreted 
by a variety of cell types involved in ocular inﬂammation 
and are also important inﬂammatory mediators in the eye. 
Although the initiating factors for most forms of uveitis in 
man are unknown, the onset of the inﬂammatory process in 
experimental models of uveitis is associated with the inﬂux 
of T-cell lymphocytes, particularly of the CD4+ subtype 
(Lightman and Chan 1990).
In experimental models of uveitis, sensitive quantitative 
techniques have shown that the BRB integrity is breached 
at the same time that T cells enter the eye, suggesting that 
T cells are responsible for this breakdown (Lightman and 
Greenwood 1992). Whether one speciﬁc T cell-secreted 
cytokine is directly responsible for this is unknown and it 
is likely that many are capable of damaging the BRB. Data 
from experimental models also suggest that the BRB can be 
damaged to variable degrees and in a patchy fashion along 
a blood vessel wall (Lightman et al 1987). More severe 
damage in one area may allow large protein macromolecules 
into the retina, whereas in a nearby area less severe damage 
may allow in only low molecular weight solutes. These 
focal areas of BRB breakdown can seal up rapidly and other 
areas may then become involved. The exact mechanism 
allowing passage of ﬂuid and molecules into the retina 
is unknown, but probably occurs via a transcellular route 
rather than through the tight junctions. As resolution of the 
inﬂammatory process occurs, cytokine production by the 
T cells is reduced, the BRB is no longer compromised, and 
abnormal ﬂuid ingress into the retina stops. Good vision may 
be restored once any remaining intraretinal ﬂuid is removed 
and the normal integrity of the BRB is restored. However, 
if the edema is chronic or very severe, permanent damage 
to the macular retinal cells may occur, with retinal thinning 
and ﬁbrosis, such that resolution of the edema ﬂuid may 
not result in return of normal vision (Guex-Crosier 1999). 
For example, eyes with bacterial or fungal endophthalmitis 
often have marked visual loss due to CME once the eye has 
been successfully treated. The over-whelming insult to the 
eye from infection and accompanying inﬂammation is likely 
to result in severe BRB damage and subsequent CME with 
signiﬁcant, permanent visual loss.
CME and pars planitis
Macular edema and consequent loss of vision are the 
most frequent and serious complications of pars planitis 
(Henderly et al 1986). Persistent macular edema for more 
than 6 to 9 months leads to chronic macular changes, with 
permanent impairment of central vision; the degree of 
impairment reﬂ  ects the severity of the changes. The pres-
ence of the pars plana exudates or membrane is more often, 
but not invariably, associated with more severe vitreous 
inﬂ  ammation and CME (Henderly et al 1987).
CME, HIV and immune recovery uveitis
Although serous macular exudation has been described in 
patients with AIDS-related cytomegalovirus retinitis, CME 
is rarely encountered in this clinical setting (Cassoux et al 
1999). However, the introduction of HAART has markedly 
changed the incidence and the prognosis of cytomegalovirus 
retinitis-related CME. In some patients the restoration of 
immune competence is associated with anterior segment 
and vitreous inﬂ  ammatory reactions resulting in chronic 
vision threatening complications including CME (Cassoux 
et al 1999; Holland GN 1999; Kersten et al 1999). Other 
inﬂ  ammatory conditions in which CME may occur include 
HLA-B27-associated acute anterior uveitis, sarcoid-
osis, birdshot retinochoroidopathy, Behcet’s syndrome, 
toxoplasmosis, Eales’ disease, idiopathic vitritis, Vogt-
Koyanagi-Harada syndrome, and scleritis (Camras et al 
1999; Dana et al 1996; Dodds et al 1999; Helm et al 1997; 
Schlaegel and Weber 1984).
Postoperative cystoid macular edema
Cystoid macular edema following cataract surgery was 
initially reported by Irvine in 1953 and is known as the 
Irvine–Gass syndrome (Irvine 1953). Approximately 20% of Clinical Ophthalmology 2008:2(4) 921
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the patients who undergo uncomplicated phacoemulsiﬁ  cation 
or extracapsular extraction develop angiographically proven 
CME (Peterson et al 1992; Jampol et al 1984). However, a 
clinically signiﬁ  cant decrease in visual acuity is seen only in 
about 1% of these eyes (Bergman and Laatikainen 1994). If 
cataract extraction is complicated by posterior capsule rupture 
and vitreous loss, severe iris trauma or vitreous traction at 
the wound, there is a signiﬁ  cantly higher incidence (up to 
20%) of clinically apparent CME, which is unrelated to the 
presence of AC-IOL (Bradford et al 1988). Clinically signiﬁ  -
cant CME usually occurs within 3–12 weeks postoperatively, 
but in some instances its onset may be delayed for months 
or many years after surgery. Spontaneous resolution of the 
CME with subsequent visual improvement may occur within 
3–12 months in 80% of the patients (Bonnet 1995). Cataract 
surgery in diabetic patients may result in a dramatic accelera-
tion of pre-existing diabetic macular edema leading to poor 
functional visual outcome. This can be prevented provided 
the severity of the retinopathy is recognized preoperatively 
and treated appropriately with prompt laser photocoagulation 
either before surgery, if there is adequate fundal view, or 
shortly afterward (Flanagan 1993). Dowler and colleagues 
(1999), in a prospective clinical and angiographic study, 
reported that 69% of the eyes in which clinically signiﬁ  cant 
macular edema arose in the ﬁ  rst 6 months after cataract 
surgery showed spontaneous resolution of macular edema. 
In contrast it persisted in all eyes in which macular edema 
had been present at the time of surgery. Studies comparing 
phacoemulsiﬁ  cation versus extracapsular cataract extraction 
in patients with diabetes revealed no difference in incidence 
of postoperative clinically signiﬁ  cant macular edema between 
the two techniques emphasizing that early intervention when 
required is more critical to outcome than choice of surgical 
technique (Dowler et al 2000). Cystoid macular edema is one 
of the leading causes of poor postoperative visual acuity after 
cataract surgery in uveitis patients. Foster and colleagues 
(1992), in a retrospective study of uveitis patients undergoing 
extracapsular cataract extraction and posterior chamber 
intraocular lens implantation, reported 46% incidence of 
postoperative macular edema but in all cases improved or 
resolved with corticosteroid therapy. It has been suggested 
that the risk of macular edema is greater in uveitis patients 
with severe postoperative uveitis and preoperative anterior 
uveitis (Okhravi et al 1999).
The etiologic role of the vitreous in aphakic CME (ACME), 
initially described by Irvine (1953) as a complication of 
vitreous traction, was endorsed by Tolentino and Schepes 
(1965). Although the actual etiologic significance of 
vitreomacular traction has been questioned by Gass and 
Norton (1966), Reese and colleagues (1967) extended this 
hypothesis by speculating that, after cataract extraction, 
vitreous traction occurred following vitreous loss or delayed 
rupture of the anterior vitreous face. The hypothesis that 
vitreomacular traction causes CME has been conﬁ  rmed 
histopathologically (Wolter 1981). Association between 
rupture of the anterior vitreous face and development of 
ACME has been proposed by several authors (Hitchings 
1977; Irvine et al 1971). Other anterior segment changes, such 
as incarceration of the anterior vitreous to the corneal wound, 
have been related to ACME. This complication is associated 
not only with increased incidence of ACME but also with a 
worse functional prognosis (Federman et al 1980).
Retinal vascular diseases
Diabetic macular edema
One of the most common causes of vision loss in patients 
with diabetes is diabetic macular edema (DME). The severity 
may range from mild and asymptomatic to profound loss of 
vision. DME is a general term deﬁ  ned as retinal thickening 
within two disc diameters of the foveal center; it can be 
either focal or diffuse in distribution. Focal edema is often 
associated with circinate rings of hard exudates (lipoprotein 
deposits) resulting from leakage from microaneurysms. 
Diffuse edema represents more extensive breakdown of the 
BRB, with leakage from both microaneurysms and retinal 
capillaries. Cystic changes may appear within the macula, 
representing focal coalescence of exudative ﬂ  uid. Clinically 
signiﬁ  cant macular edema (CSME) is a form of DME that was 
precisely deﬁ  ned by the Early Treatment Diabetic Retinopa-
thy Study (ETDRS) (Early Treatment Diabetic Retinopathy 
Study Research Group 1985, 1987). CSME exists if any of 
the following criteria are met:
•  Any retinal thickening within 500 μm of the foveal 
center.
•  Hard exudates within 500 μm of the foveal center that are 
associated with adjacent retinal thickening (which may 
lie more than 500 μm from the foveal center).
•  An area of retinal thickening at least 1 disc area in size, 
any part of which is located within 1 disc area of the 
foveal center.
The physics of diabetic macular edema are governed by a 
pair of hydrodynamic principles, Starling’s law and LaPlace’s 
law (Gardner et al 2002). Starling’s law states that the net move-
ment of ﬂ  uid and molecules across the vessel wall is determined 
by the interplay between lumenal hydrostatic pressure, which 
drives ﬂ  uid out of the vessel, and plasma colloid osmotic Clinical Ophthalmology 2008:2(4) 922
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pressure, which draws ﬂ  uid into the vessel. Lumenal hydrostatic 
pressure is often increased in diabetic eyes, due in part to 
coexisting systemic hypertension and in part to the increase in 
hydrostatic pressure that arises from focal retinal hypoxia. This 
favors the egress of ﬂ  uid from vessels and increases the likeli-
hood of developing macular edema. LaPlace’s law states that 
a vessel will react to increased lumenal hydrostatic pressure by 
both dilating and becoming more tortuous. As a consequence, 
tight junctions between endothelial cells may become disrupted, 
again favoring ﬂ  uid egress and macular edema.
Retinal vein occlusion
Retinal vein obstructions represent another common retinal 
vascular cause of CME. In patients with central retinal vein 
occlusion or a tributary branch occlusion involving the macula, 
CME is a major cause of visual loss. This edema, if severe or 
chronic (8 months), causes permanent diminution of vision 
secondary to disruption of the microscopic intraretinal con-
nections and to the intracellular damage suffered by the visual 
elements (Coscas and Gaudric 1984). Persistent CME may be 
associated with vitreomacular attachment or hyperlipidemia 
and cardiovascular history, whereas it is inversely correlated 
to glaucoma (Glacet-Bernard et al 1996; Hikichi et al 1995). 
Finkelstein (1992) suggested that ischemic CME following 
branch retinal vein occlusion is often transient and, compared 
to perfused CME, has better prognosis for visual acuity. 
Another important sign of CME following obstructive venous 
retinopathy is the development of ﬂ  uid blood levels in central 
cystoid spaces. Although ﬂ  uid blood levels can occasionally 
be seen in diabetic, aphakic, or pseudophakic macular edema 
its occurrence is signiﬁ  cantly more common in retinal vein 
occlusion. Therefore any diabetic patient displaying such a 
clinical ﬁ  nding should be suspected of having obstructive 
venous disease (Jones 1998).
Diagnostic methods
Slit-lamp examination with contact or noncontact lens makes 
it possible to detect retinal thickening, localized or extending 
to the posterior pole. The use of a narrow slit beam is useful 
in detecting cystoid spaces. Tests may be grouped into 
three categories according to whether one is analyzing the 
underlying pathogenesis, the effect of the macular edema on 
the retina, or its impact on visual function.
Tests detecting disturbances 
in the blood–retinal barrier
Macular edema may result from the breakdown of the BRB. 
This may occur at the level of the retinal pigment epithelium or 
the capillary endothelial cells. Various methods of investigation 
are utilized to detect disruption of the BRB in order to 
determine the presence and the extent of macular edema.
The fundus ﬂ  uorescein angiogram is clinically the most 
widely available and useful test. It permits study of the 
circulation of the retina and choroid in normal and diseased 
states (Jaffe et al 1981). The amount of ﬂ  uorescein leakage 
depends on the dysfunction of the retinal vascular endothe-
lium. Although there is a signiﬁ  cant correlation between 
visual acuity and the area covered by these cystoid changes, 
there is no relation between visual acuity and distance of cysts 
from the foveal avascular zone (Gass et al 1985). Fundus 
ﬂ  uorescein angiography, apart from being a signiﬁ  cant 
diagnostic modality also improves the accuracy of planning 
treatment for macular edema (Kylstra et al 1999). Late-phase 
stereoscopic pairs are useful in estimating the retinal thick-
ness, the level of the leakage and the location and extent of 
cystic spaces.
Tests detecting retinal tissue thickness
Assessment of retinal thickness can be useful in the treatment 
and follow-up of macular edema. Retinal thickness at the 
posterior pole can be assessed by several methods. Because 
slit-lamp biomicroscopy and stereoscopic fundus photography 
are to some extent subjective, new imaging techniques for 
objective measurement of retinal thickness have been intro-
duced to clinical use. The two most commonly used techniques 
are the OCT and the retinal thickness analyzer (RTA).
Optical coherence tomography is a noninvasive device 
that obtains cross-sectional, high-resolution images of the 
retina and thus may detect retinal thickening (Huang et al 
1991). Microstructural features are determined by measuring 
the ‘echo’ time it takes for the light to reﬂ  ect from the dif-
ferent structures at varying distances, analogous to A-scan 
ultrasonography. As the OCT operates with a near-infrared 
wavelength (about 840 nm), the examination is of minimal 
discomfort for the patient (Ripandelli et al 1998). Optical 
coherence tomography examination is possibly indicated in 
the early detection and follow-up of patients with macular 
edema (Hee et al 1998). It has been shown to produce highly 
reproducible measurements and it is as effective at detecting 
macular edema as ﬂ  uorescein angiography, but is superior 
at demonstrating axial distribution of the ﬂ  uid (Hee et al 
1998; Browning et al 2008). The RTA is a rapid screening 
instrument that generates a detailed map of retinal thickness 
(Zeimer et al 1989). Multiple cross sectional imaging gener-
ates a 3D reconstruction of the retina. The major advantage 
of the RTA is the option to scan a relatively wide area of Clinical Ophthalmology 2008:2(4) 923
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the retina in a short acquisition time. It has been shown that 
RTA is a useful and sensitive tool, which provides objective 
measurement of the retinal thickness, facilitating the diag-
nosis and follow-up of diabetic macular edema, as well as 
evaluation of the efﬁ  cacy of laser treatment in this condition 
(Zeimer et al 1989).
The scanning laser ophthalmoscope (SLO) has also been 
utilized in order to quantify retinal thickness by ophthal-
moscopy and retinal topography (Oshima et al 1999) It is a 
rapid and noninvasive imaging method that provides quan-
titative analysis of macular cysts in addition to qualitative 
information not seen clinically (Mainster et al 1982). The 
chief advantage of the SLO is scanning a small focused spot 
to generate an image (rather than illuminating a large area), 
which provides a high contrast image. The infrared imaging 
of the SLO offers advantages over current imaging techniques 
by minimizing light scatter through cloudy media.
Tests assessing retinal function
Macular edema may potentially affect macular function as far 
as visual acuity and contrast sensitivity are concerned. Tests 
assessing macular function may be used indirectly to detect the 
effects of macular edema and follow up its treatment. Contrast 
sensitivity charts and electroretinography are both clinical and 
experimental tools. Contrast sensitivity has been documented 
as suffering speciﬁ  c changes in CME as well as other localized 
and generalized retinal disorders (Ghafour et al 1982). Ibanez 
and colleagues in a prospective comparative study evaluated 
the effect of pseudophakic CME on contrast sensitivity. They 
reported a statistically signiﬁ  cant decrease in contrast sensitiv-
ity for patients who developed transient or persistent pseudo-
phakic CME for all spatial frequencies studied at two months 
and for higher frequencies at 8.5 months following surgery, as 
opposed to no CME group. Reduction in contrast sensitivity 
may account for persistent difﬁ  culties experienced by patients 
despite good Snellen acuity (Ibanez et al 1993).
Electroretinography may also be utilized to follow up 
the treatment of macular edema. The focal electroretinogram 
(ERG) is the response evoked by the foveal cones of 
the retina to a brief ﬂ  ash of light focused on the fovea 
(Miyake et al 1993; Salzman et al 1986; Weiner et al 
1997). The foveal ERG provides objective information on 
the presence or absence of organic disease at the macula. 
A very important development in the ERG-ﬁ  eld in recent 
years is the multifocal-ERG recording system. This system 
allows assessment of ERG activity in small areas of retinal 
dysfunction. The multifocal-ERG introduced by Sutter 
and Tran (1992) allows the derivation simultaneously of 
61 or 102 local ERG signals in a central visual ﬁ  eld of about 
60° diameter around the fovea in a considerably short time 
of 4 to 8 minutes. So the decrease or retinal function due to 
regional disorders in the outer retinal layers can be described 
in details by this technique, which allows the functional 
mapping of the retina (Sutter and Tran 1992).
Treatment
Medical
The challenge concerning the management of macular edema 
arises in the chronic and persistent case, for which a stepwise 
therapeutic approach is optimal. The clinician must always 
be alert to the possible side effects of the many effective, 
but potentially toxic, pharmaceutical agents used to treat 
this entity. Additionally, surgical management should be 
considered for unremitting cases of CME.
Nonsteroidal antiinﬂ  ammatory drugs
In aphakic or pseudophakic CME, the occurrence of intraocular 
inﬂ  ammation with synthesis of prostaglandins results in disrup-
tion of the tight junctions of the perifoveal retinal capillaries. 
Nonsteroidal anti-inﬂ  ammatory drugs (NSAIDs) are useful as 
they inhibit the enzyme cyclooxygenase, which is required for 
the production of the prostaglandins as a degradation product 
of arachidonic acid. There is evidence that some NSAIDs 
may also act on other mediators. Experimental data showed 
that diclofenac at high concentrations inhibits the formation 
of lipoxygenase products (5-hydroxyeicosatetraenoic acid, 
leukotrienes) suggesting an additional regulatory role in the 
lipoxygenase pathway. However, the clinical relevance of 
the above property is still to be determined (Flach 2002). 
Topical NSAIDs, including ketorolac tromethamine 0.5%, 
indomethacin 1%, and diclofenac 1%, are available and have 
been used either for treatment of macular edema following 
cataract surgery (Burnett et al 1983) or prophylactically to 
prevent angiographic edema (Jampol et al 1984). Although 
there is a multiplicity of studies addressing the issue of topical 
administration of NSAIDs for the prophylaxis or treatment of 
postoperative CME, the majority of them have not been ran-
domized, or have had inadequate controls. In addition there is 
a diversity of ﬁ  nal outcomes as some of the authors evaluate 
angiographic macular edema and others clinically signiﬁ  cant 
CME, whereas most relevant outcomes such as visual acuity 
have been used only in a few studies.
Carbonic anhydrase inhibitors
Medical treatment of CME with carbonic anhydrase inhibitors 
(CAIs) has been known for over a decade (Cox et al 1988). Clinical Ophthalmology 2008:2(4) 924
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Carbonic anhydrase inhibitors may alter the polarity of the 
ionic transport systems in the retinal pigment epithelium 
through the inhibition of carbonic anhydrase and γ-glutamyl 
transferase. As a result there is increased ﬂ  uid transport across 
the retinal pigment epithelium from the sub-retinal space to 
the choroid with reduction of the edema. Carbonic anhydrase 
inhibitors have also been shown to have other direct effects 
both on retinal and retinal pigment epithelial cell function by 
inducing an acidiﬁ  cation of the sub-retinal space, a decrease 
of the standing potential as well as an increase in retinal 
adhesiveness (Kita and Marmor 1992). Acetazolamide appears 
to be a particularly useful therapeutic agent in the management 
of macular edema due to retinitis pigmentosa (RP). A random-
ized crossover study reported improvement of visual acuity in 
more than 80% of all patients who received acetazolamide. The 
therapeutic effect may be independent of the reduction of mac-
ular edema, as judged by ﬂ  uorescein angiography (Fishman 
et al 1989). A suggested treatment protocol includes a normal 
clinical starting dose of CAI of 500 mg/day, which should be 
continued for at least 1 month to see an effect. The patients 
may reduce this dose over the course of therapy according to 
the subjective impression of treatment response.
Steroids
Steroids also inhibit the production of prostaglandins, but at 
a higher level in the biochemical pathway, by inhibiting the 
enzyme phospholipase A2, which catalyses the conversion 
of membrane lipids to arachidonic acid. By this process, 
steroids inhibit the formation of both prostaglandins and 
leukotrienes (Abe et al 1999). Locally their vasoconstrictive 
properties decrease intracellular and extracellular edema, 
suppress macrophage activity, and decrease lymphokine 
production. Corticosteroids may be administered topically, 
by periocular injection, orally and parenterally. Topical 
corticosteroids penetrate the corneal epithelium and reach 
the anterior chamber. The antiinﬂ  ammatory properties of 
topical corticosteroids can be potentially helpful in treating 
CME caused by chronic iritis or iridocyclitis. Although the 
most common form of administration of systemic steroids 
is oral, there are published reports of series using high-
dose intravenous methylprednisolone for severe ocular 
inﬂ  ammatory disease (Wakeﬁ  eld et al 1986) and for persistent 
pseudophakic CME with satisfactory results (Abe et al 1999). 
Intravitreal injection of triamcinolone acetonide has become a 
popular treatment, subsequently, a number of corticosteroid-
based intravitreal implants have been developed to provide 
a sustained release of drug and make repeated intravitreal 
injections unnecessary. A promising treatment modality for 
patients poorly controlled or intolerant to repeated periocular 
corticosteroid injections, systemic corticosteroids, or steroid 
sparing immunosupressive agents has been suggested with 
the introduction of intraocular steroid-sustained drug delivery 
devices. It has been shown that these devices are nontoxic 
and produce constant intraocular drug levels for an extended 
period in human and experimental models (Hainsworth et al 
1996; Jaffe et al 1996). There are currently four corticosteroid-
based intravitreal implants under development. These include 
the dexamethasone biodegradable implant (Posurdex®, 
Allergan, Irvine, CA), the helical triamcinolone acetonide 
implant (I-vation™ TA, SurModics, Eden Prairie, MN), the 
ﬂ  uocinolone acetonide implant (Retisert®, Bausch and Lomb, 
Rochester, NY), and the ﬂ  uocinolone acetonide – based 
implant that is injectable (Medidur™, pSivida, Boston, 
MA/Alimera Sciences, Alpharetta, GA). Triamcinolone 
acetonide has been reported to be effective in the manage-
ment of macular edema (Jonas et al 2003; Loewenstein 
and Goldstein 2006). because it suppresses inﬂ  ammation, 
reduces extravasation of ﬂ  uid from leaking blood vessels, 
inhibits ﬁ  brovascular proliferation, and downregulates pro-
duction of VEGF (Binz et al 2006). Triamcinolone can be 
administered by several routes, including intravitreal depot 
injection, periocular injection, posterior subtenon injection, 
and intravitreal implant. After depot injection, corticosteroid 
action peaks at 1 week, with residual activity persisting 
for 3 to 6 months. Intravitreal injection of triamcinolone is 
associated with signiﬁ  cant adverse events, including elevated 
intraocular pressure in up to half of injected eyes (Jonas 
et al 2003) and cataract formation (Avitabile et al 2005; 
Loewenstein and Goldstein 2006), as well as injection-related 
complications such as endophthalmitis (Avitabile et al 2005; 
Loewenstein and Goldstein 2006) and retinal detachment 
(Androudi et al 2005). The efﬁ  cacy of intravitreal use of 
triamcinolone acetonide was assessed by multifocal-ERG 
recording and OCT by Koutsandrea and colleagues (2007) 
and the results showed a real improvement of central retinal 
thickness and increase of the electrical activity of the foveal 
and perifoveal area 6 months after treatment (Figure 1). 
Periocular injections reduce the risk of serious complications 
such as endophthalmitis, but the duration of effect is shorter, 
and the therapeutic efﬁ  cacy of triamcinolone administered by 
this route against DME is unclear.
Surgical
Laser photocoagulation
Photocoagulation is a therapeutic technique using a strong 
light source to coagulate tissue. Several theories attempted Clinical Ophthalmology 2008:2(4) 925
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to explain the beneﬁ  cial effect of laser photocoagulation to 
macular edema. Laser lesions in experimental animals show a 
temporary breakdown of the BRB and a subsequent repair, as 
the retinal pigment epithelium cells adjacent to the burns pro-
liferate and slide to replace the necrotic cells. The new retinal 
pigment epithelium cells produce tight junctions within several 
weeks, which restore the integrity of the retinal pigment epithe-
lium barrier (Androudi et al 2005). An alternative hypothesis 
states that the grid laser by destroying photoreceptors reduces 
the oxygen consumption of the outer retina and allows oxygen 
to diffuse from the choroid to the inner retina, where it raises 
the oxygen tension and relieves hypoxia (Central Vein Occlu-
sion Study Group 1995). This increased oxygen tension causes 
retinal arteriolar constriction and increased resistance in the 
arterioles, leading to reduced hydrostatic pressure in the capil-
laries and venules. The decreased hydrostatic pressure causes 
vessel constriction according to Laplace’s law, vessel shorten-
ing, and less ﬂ  ux of ﬂ  uid from vessel to tissue as is postulated 
in Starling’s law (Molnar et al 1985). Diabetic macular edema 
and macular edema following branch retinal vein occlusion 
may improve following focal or grid laser photocoagulation. 
Laser treatment is not indicated for predominantly ischemic 
maculopathy. Most authors agree that the prognosis is best 
with localized leakage with or without circinate rings of hard 
exudates (The Branch Vein Occlusion Study Group 1984; The 
Early Treatment Diabetic Retinopathy Study Research Group 
1987). Should PRP be also needed, this should be carried out 
after or in conjunction with macular treatment, because post-
PRP inﬂ  ammation and altered retinal blood ﬂ  ow may result in 
deterioration of macular edema. Focal laser treatment aims to 
close or obliterate the microaneurysms producing focal areas 
of leakage (The Branch Vein Occlusion Study Group 1984). 
Grid photocoagulation may reduce leakage attributable to 
permeability abnormalities within dilated macular capillaries, 
with a positive effect on visual acuity and ﬂ  uorescein leak-
age in diffuse diabetic macular edema, radiation retinopathy, 
and macular edema due to branch retinal vein occlusion. 
Side effects such as scotomas, corresponding to the laser 
burns, have been frequently noticed by the patients following 
photocoagulation. These scotomas generally fade over a period 
of several weeks. Symptoms are more likely to occur if laser 
burns are placed too close to each other.
Vitrectomy
Diabetic macular edema
Vitrectomy can be useful in eyes with DME if there is evidence 
of vitreomacular traction. There is a higher rate of posterior 
vitreous detachment in eyes without DME than in diabetic 
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Figure 1 A 58-year-old man with pseudophakic CME. The pretreatment OCT shows an increase of the central retinal thickness (A), and the mf-ERG reveals a craterlike 
depression of the foveal and perifoveal area (B).Twelve months after treatment the OCT depicts the improvement of the central retinal thickness (C) and the mf-ERG shows 
a real recovery of the electrical activity of the foveal (area 1) and parafoveal (area 2) area (D).
Abbreviations: CME, cystoid macular edema; mf-ERG, multifocal electroretinogram; OCT, optical coherence tomography.Clinical Ophthalmology 2008:2(4) 926
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eyes with DME (Nasrallah et al 1988). In one published series, 
vitrectomy resulted in a 61% to 73% resolution of edema in 
DME cases without overt vitreoretinal interface abnormalities 
(Recchia et al 2005). Supplementing vitrectomy with the 
removal of the internal limiting membrane may improve 
outcomes, with one study showing that this approach provides 
better visual outcomes than a single session of modiﬁ  ed grid 
laser in relieving persistent diffuse DME (Mason et al 2006). 
Vitrectomy is not without complications. Cataract formation 
is common, retinal detachments and recurrent vitreous 
hemorrhage may occur and intraocular pressure (IOP) may 
rise, leading to glaucoma.
Aphakic/pseudophakic CME
The Vitrectomy-Aphakic-Cystoid Macular Edema Study, a 
prospective, multicenter study of patients with chronic aphakic 
CME, showed signiﬁ  cant improvement in visual acuity following 
vitrectomy (Fung 1985). In eyes with vitreous loss at the time 
of cataract surgery and subsequent development of vitreous 
adhesions to anterior segment structures, lysis of vitreous strands 
to the cataract wound with the aid of Nd: YAG laser may reduce 
vitreous traction leading to resolution of CME (Katzen 1983).
Future treatments
Breakdown of the capillary BRB, causing macular edema, 
appears to be dependent on a number of active processes 
that may be open to pharmacological manipulation. In 
diabetes mellitus, hyperglycemia has been found to result 
in increased levels of dialglycerol, which in turn activates 
the protein kinase C (PKC) pathway. The latter functions as 
signal for growth factors, especially the vascular endothelial 
growth factor (VEGF), which plays a dominant role in retinal 
vascular leakage and formation of macular edema (Koya and 
King 1998). Experimental studies have clearly shown that 
blockage of VEGF action by inhibiting PKC β may prevent 
the above process (Aiello et al 1995). Recently investigators 
have largely concentrated on LY333531, which is a highly 
selective inhibitor for the PKC β isoform that has very little 
affect on other enzymes, minimizing the risk of systemic side 
effects resulting from its use. A randomized, double-masked, 
placebo-controlled study in diabetic patients of less than 10 
years duration and no or mild retinopathy has reported normal-
ization of retinal blood ﬂ  ow in patients treated with LY333531 
as opposed to placebo-treated subjects (Aiello et al 1999).
Anti-VEGF treatment
Inhibition of VEGF has become a topic of interest in recent 
years in the area of age-related macular degeneration. 
The properties of VEGF, and the consequences of its 
inhibition, also suggest a role for this approach in the 
management of DME.
In the pathophysiologic cascade leading to DME, 
chronic hyperglycemia leads to oxidative damage to endo-
thelial cells as well as to an inﬂ  ammatory response. The 
ensuing ischemia results in overexpression of a number of 
growth factors, including not only VEGF but also insulin-
like growth factor-1, angiopoeitin-1 and -2, stromal-derived 
factor-1, ﬁ  broblast growth factor-2, and tumor necrosis 
factor (Grant et al 2004). Synergistically, these growth 
factors mediate angiogenesis, protease production, endo-
thelial cell proliferation, migration, and tube formation. 
Tumor necrosis factor-α (TNF-α) and VEGF play a role 
in the early stages of angiogenesis, with TNF-α promoting 
leukocyte adhesion and VEGF promoting leukostasis, 
resulting in ischemia.
Blockade of all involved growth factors will likely be 
necessary to completely suppress the detrimental effects 
of ischemia, but even isolated blockade of VEGF may 
have beneficial effects on DME. VEGF increases vascu-
lar permeability by relaxing endothelial cell junctions, 
which increases permeability and leakage. Inhibition of 
VEGF blocks this effect to some extent, as demonstrated 
in several recent clinical trials and case series involving 
the anti-VEGF molecules pegaptanib, ranibizumab, and 
bevacizumab. Pegaptanib sodium (Macugen®, Eyetech 
Pharmaceuticals, Melville, NY/Pfizer, New York, NY) is 
an anti-VEGF aptamer, a small piece of RNA that self-
folds into a shape that binds to and blocks the effects of 
VEGF165, one isoform of the VEGF family of molecules. 
The drug is approved by the FDA for the treatment of 
age-related macular degeneration, and it has recently 
been studied in a phase II trial for DME (Cunningham 
et al 2005). In that study, 172 subjects with DME were 
randomized to receive a series of 3 intravitreal injections 
of pegaptanib (at entry and every 6 weeks) in 1 of 3 doses, 
or a sham injection, and were followed for 36 weeks. 
Additional injections or photocoagulation were permit-
ted every 6 weeks through the end of the study. A total 
of 52% of patients in the 0.3-mg and sham groups had 
baseline visual acuity of 58 letters; the remaining 48% 
had baseline visual acuity of 58 letters. At the 36-week 
mark, mean visual acuity had improved to 20/50 in the 
pegaptanib 0.3-mg group (the dose that was approved by 
the FDA) versus only 20/63 in the sham group (P = 0.04). 
Mean central retinal thickness decreased by 68 mcm in 
the 0.3-mg group, whereas it increased by 4 mcm in the Clinical Ophthalmology 2008:2(4) 927
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sham group (P = 0.02). In addition, photocoagulation was 
required in 25% of the 0.3-mg group compared with 48% 
of the sham group (P = 0.04). The injections were well 
tolerated, with a single case of endophthalmitis reported 
(1/652 injections, 0.15%).
Ranibizumab (Lucentis™, Genentech, San Francisco, 
CA) is an antibody fragment that also binds and blocks 
the effects of VEGF. Unlike pegaptanib, ranibizumab 
binds and inhibits all isoforms of VEGF. Ranibizumab is 
also approved by the FDA for the treatment of age-related 
macular degeneration. A small, single-site, open-label trial 
was conducted in which 10 patients with DME were treated 
with a series of 3 monthly injections of 1 of 2 doses of 
ranibizumab (0.3 or 0.5 mg; the FDA approved the latter 
for macular degeneration) and then followed for 2 years 
(Chun et al 2006). Recently published data from this study 
indicate that at 3 months, 4 patients gained 15 or more letters 
of vision, 5 patients gained 10 or more letters, and 8 patients 
gained at least 1 letter. Mean central retinal thickness was 
reduced by 45 μm in the 0.3-mg group and by 198 μm in 
the FDA-approved 0.5-mg group.
Bevacizumab (Avastin®, Genentech, San Francisco, CA) 
is the full antibody from which ranibizumab is derived. This 
anti-VEGF molecule is FDA approved for systemic treatment 
of metastatic colon cancer, but not for any ophthalmic 
indications. Its use in conditions such as age-related macular 
degeneration, diabetic retinopathy, and DME is currently 
off-label.
A small, retrospective review of 16 eyes of 15 patients 
with macular edema secondary to central retinal vein 
occlusion recently reported the short-term anatomic and 
visual acuity outcomes after treatment with intravitreal 
bevacizumab (Iturralde et al 2006). Subjects received at 
least one injection of bevacizumab 1.25 mg, with repeat 
injections at 1 month at the investigator’s discretion, with 
a mean of 2.8 injections per eye. One month after the 
initial injection, mean central macular thickness measured 
by OCT decreased from 887 to 372 μm (P  0.001). 
Mean visual acuity improved from the pretreatment 
baseline of 20/600 to 20/200 at 1 month (P = 0.001) and 
to 20/138 at 3 months (P  0.001). In all, 14 of the 16 
eyes demonstrated a halving of the visual angle, and no 
adverse events were noted. In a recent study, Moschos 
and Moschos (2008) showed that 3 months after the 
intravitreal use of bevacizumab, the electrical activity of 
the fovea and perifovea increased significantly (Figure 2, 
Figure 3). Anti-VEGF therapy for DME shows promise 
in preliminary studies. Larger studies are ongoing. VEGF 
Figure 2 OCT recordings of the right eye of a 60-year-old male patient at presentation 
(A), 1 month after treatment (B) and 3 months after treatment (C). The pretreatment 
OCT showed an increase of central retinal thickness. Three months after treatment 
the OCT depicted the decrease of the retinal thickness of the fovea.
Abbreviation: OCT, optical coherence tomography.
0 10 20
nV/deg2
0 10 20
nV/deg2
0 10 20
nV/deg2
1 µV
100 ms
1 µV
100 ms
1 µV
100 ms
A
B
C
Figure 3 3D topographic plot and mf-ERG traces of the same eye at presentation 
(A), 1 month after treatment (B) and 3 months after treatment (C). Before treatment 
the mf-ERG revealed a craterlike depression of the foveal and perifoveal area. Three 
months after treatment the mf-ERG showed an improvement of the electrical activity 
of the fovea (area 1) and perifovea (area 2).
Abbreviations: 3D, three dimensional; mf-ERG, multifocal electroretinogram.Clinical Ophthalmology 2008:2(4) 928
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inhibition may represent an important component of DME 
therapy in the future. Improvements in drug delivery 
will be necessary in order to avoid repeated intravitreal 
injections and the cumulative risk of endophthalmitis 
associated with this route of administration.
Method of literature search
In this review, we identiﬁ  ed pertinent articles on macular 
edema from a combination of sources including electronic 
database searches and manual searches through the 
literature. A computerized search of the PubMed database 
(National Library of Medicine) was performed up to 
January 2008. The term ‘macular edema’ was used for a 
broad and sensitive search. Subsequently all the abstracts 
were carefully scanned and were divided into subcategories 
covering topics including ‘pathogenesis’, ‘etiology’, ‘clinical 
manifestations’, ‘investigations and treatment of macular 
edema’. Non-English articles were included when deemed 
necessary. Copies of the entire articles were obtained. 
Reference lists of identiﬁ  ed sources were used to glean more 
articles on the same topic. Additional books cited from these 
references were also used.
Disclosure
The authors report no conﬂ  icts of interest in this work.
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